![]() |
Microscopy pictures of three-dimensional lung cancer spheroids transfected with green fluorescent-labelled ASOs. Credit: UniBE / NCCR RNA & Disease |
Researchers of the University of Bern and the Insel Hospital, University Hospital Bern, have developed a screening method to discover new drug targets for cancer treatment in the so-called “Dark Matter” of the genome. They applied their method to non-small cell lung cancer (NSCLC), the greatest cancer killer for which effective therapies are urgently sought. They could show that inhibiting identified targets could greatly slow down cancer growth, and their method is adaptable to other cancers.
Cancer is in Switzerland the second leading cause of death. Among the different types of cancers, non-small cell lung cancer (NSCLC) kills most patients and remains largely incurable. Unfortunately, even newly approved therapies can extend the life of patients by only a few months and only a few survive the metastatic stadium long-term. Thus, new treatments which attack cancer in novel ways are sought. In a recently published study in the Journal Cell Genomics, researchers of the University of Bern and the Insel Hospital determined new targets for drug development for this cancer type.